| Pembrolizumab cutaneous adverse events and their association with disease progression M Sanlorenzo, I Vujic, A Daud, A Algazi, M Gubens, SA Luna, K Lin, ... JAMA dermatology 151 (11), 1206-1212, 2015 | 450 | 2015 |
| The risk of melanoma in airline pilots and cabin crew: a meta-analysis M Sanlorenzo, MR Wehner, E Linos, J Kornak, W Kainz, C Posch, I Vujic, ... JAMA dermatology 151 (1), 51-58, 2015 | 137 | 2015 |
| Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV) L Borradori, N Van Beek, C Feliciani, B Tedbirt, E Antiga, R Bergman, ... Journal of the European Academy of Dermatology and Venereology 36 (10), 1689 …, 2022 | 127 | 2022 |
| Melanoma immunotherapy M Sanlorenzo, I Vujic, C Posch, A Dajee, A Yen, S Kim, M Ashworth, ... Cancer biology & therapy 15 (6), 665-674, 2014 | 105 | 2014 |
| Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma M Sanlorenzo, A Choudhry, I Vujic, C Posch, K Chong, K Johnston, ... Journal of the American Academy of Dermatology 71 (6), 1102-1109. e1, 2014 | 93 | 2014 |
| DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics A Latorre, C Posch, Y Garcimartín, A Celli, M Sanlorenzo, I Vujic, J Ma, ... Nanoscale 6 (13), 7436-7442, 2014 | 80 | 2014 |
| Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer I Vujic, M Sanlorenzo, C Posch, R Esteve-Puig, AJ Yen, A Kwong, ... Oncotarget 6 (2), 969, 2015 | 76 | 2015 |
| The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients C Posch, B Monshi, T Quint, I Vujic, N Lilgenau, K Rappersberger Journal Of The American Academy Of Dermatology 77 (1), 123-129. e5, 2017 | 74 | 2017 |
| Mycoplasma pneumoniae‐associated mucositis – case report and systematic review of literature I Vujic, A Shroff, M Grzelka, C Posch, B Monshi, M Sanlorenzo, ... Journal of the European Academy of Dermatology and Venereology 29 (3), 595-598, 2015 | 71 | 2015 |
| Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma C Posch, BD Cholewa, I Vujic, M Sanlorenzo, J Ma, ST Kim, S Kleffel, ... Journal of Investigative Dermatology 135 (10), 2475-2483, 2015 | 65 | 2015 |
| Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis* T Graier, W Salmhofer, C Jonak, W Weger, C Kölli, B Gruber, PG Sator, ... British Journal of Dermatology 184 (6), 1094-1105, 2021 | 62 | 2021 |
| Apremilast in psoriasis–a prospective real‐world study I Vujic, R Herman, M Sanlorenzo, C Posch, B Monshi, K Rappersberger, ... Journal of the European Academy of Dermatology and Venereology 32 (2), 254-259, 2018 | 62 | 2018 |
| Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients B Monshi, C Posch, I Vujic, A Sesti, S Sobotka, K Rappersberger Journal of the American Academy of Dermatology 71 (4), 738-744, 2014 | 60 | 2014 |
| Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma P Curl, I Vujic, LJ van ‘t Veer, S Ortiz-Urda, JG Kahn PloS one 9 (9), e107255, 2014 | 58 | 2014 |
| The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis P Dapavo, I Vujic, MT Fierro, P Quaglino, M Sanlorenzo Journal of the American Academy of Dermatology 75 (4), 736-739, 2016 | 50 | 2016 |
| The burden of malignant melanoma–lessons to be learned from Austria B Monshi, M Vujic, D Kivaranovic, A Sesti, W Oberaigner, I Vujic, ... European journal of cancer 56, 45-53, 2016 | 46 | 2016 |
| The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes M Sanlorenzo, I Vujic, C Posch, JE Cleaver, P Quaglino, S Ortiz-Urda JAMA dermatology 151 (4), 450-452, 2015 | 46 | 2015 |
| Phosphoproteomic analyses of NRAS (G12) and NRAS (Q61) mutant melanocytes reveal increased CK2α kinase levels in NRAS (Q61) mutant cells C Posch, M Sanlorenzo, I Vujic, JA Oses-Prieto, BD Cholewa, ST Kim, ... Journal of Investigative Dermatology 136 (10), 2041-2048, 2016 | 39 | 2016 |
| Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells I Vujic, M Sanlorenzo, R Esteve-Puig, M Vujic, A Kwong, A Tsumura, ... Oncotarget 7 (6), 7297, 2016 | 38 | 2016 |
| BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti–PD-1 antibody M Sanlorenzo, I Vujic, A Floris, M Novelli, L Gammaitoni, L Giraudo, ... Clinical Cancer Research 24 (14), 3377-3385, 2018 | 37 | 2018 |
